The 18 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 123.50, with a high estimate of 192.00 and a low estimate of 86.00. The median estimate represents a +54.22% increase from the last price of 80.08.
The current consensus among 21 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.18
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.